

Clinical trial results
for previously
treated advanced
kidney cancer
For certain adults with previously treated advanced
kidney cancer (renal cell carinoma)
Clinical trial results
for previously
treated advanced
kidney cancer
For certain adults with previously treated advanced
kidney cancer (renal cell carinoma)
Actor portrayals.
In a clinical trial of 821 people with previously treated advanced kidney cancer, 410 people were given OPDIVO and 411 people were given everolimus, a standard treatment.
Half the people were alive
Half the people were alive
In a clinical trial, people given OPDIVO had a 27% lower risk of dying than those given everolimus.
In a clinical trial, tumors shrinking or disappearing completely because of treatment is known as the overall response rate.
Words to know
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
OPDIVO will not work for everyone. Individual results may vary.
It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)
For adults with previously treated advanced kidney cancer (renal cell carcinoma)
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with kidney cancer (renal cell carcinoma) when your cancer has spread after treatment with other cancer medications.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For subcutaneous injection
OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used to treat adults with kidney cancer (renal cell carcinoma) when your cancer has spread after treatment with other cancer medications.
It is not known if OPDIVO Qvantig is safe and effective in children.